sorafenib has been researched along with oleylamide in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (oleylamide) | Trials (oleylamide) | Recent Studies (post-2010) (oleylamide) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 197 | 0 | 63 |
| Protein | Taxonomy | sorafenib (IC50) | oleylamide (IC50) |
|---|---|---|---|
| Transient receptor potential cation channel subfamily V member 2 | Rattus norvegicus (Norway rat) | 2.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, XD; Liu, H; Qin, SK; Tao, L; Tong, XH; Wang, ZS; Wu, Q; Yang, Y; Zheng, RS | 1 |
1 other study(ies) available for sorafenib and oleylamide
| Article | Year |
|---|---|
Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Communication; Cell Line, Tumor; Cell Proliferation; Connexins; Drug Synergism; Gap Junctions; Glycyrrhetinic Acid; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Oleic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tretinoin | 2014 |